ZYME Q3 2019 Earnings — Zymeworks Inc. Revenue & Financial Results | Market Cap Arena

ZYMEZymeworks Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+282.7% YoY

Gross Profit

-$21M-272.2% margin

Operating Income

-$34M-427.0% margin

Net Income

-$30M-387.7% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$21M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$400M

Total Liabilities

$91M

Stockholders' Equity

$310M

Cash & Equivalents

$251M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+282.7%
Gross Profit	-$21M	-$12M	-76.2%
Operating Income	-$34M	-$20M	-71.8%
Net Income	-$30M	-$19M	-62.5%

Revenue Segments

Option Exercise Fee

$8M66%

Commercial License Option Exercise

$4M31%

License and Service

$336,0003%

Research Support And Supplies Payments

$24,0000%